Notably, mTOR inhibitors (e.g., sirolimus, everolimus) demonstrate therapeutic efficacy in TSC by modulating aberrant signaling, achieving seizure frequency reduction in 50% of patients and seizure-free outcomes in select cases (6). This evidence concerns the gene MTOR and tuberous sclerosis.